ClinicalTrials.gg
CompletedNCT00624442Updated May 14, 2021Results posted

A Study of CK-1827452 Infusion in Stable Heart Failure

A Phase 2 interventional study of CK-1827452 and CK-1827452 in Heart Failure, sponsored by Cytokinetics. Completed at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-14.

Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.

Enrollment
8th of 14
45 · median 48
Started
2007
the only one that year
Phase 2
7 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
14 of 14
Cytokinetics

Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 8th largest by enrollment, is the only one that started in 2007, is one of 7 in phase 2, and was the 1st registered.

Heart Failure

6,332 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About omecamtiv mecarbil

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omecamtiv mecarbil in Heart Failure, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability, and pharmacodynamics of CK-1827452 infusion in patients with stable heart failure.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is male, or female of non- (two years or surgically sterilized)
  2. Female patients must have a negative urine pregnancy test prior to entry into the study
  3. Patient is 18 years old or greater
  4. Patient has given signed
  5. Patient is considered to be in suitable health in the opinion of the investigator, as determined by:

    • A pre-study physical examination with no clinical abnormalities which in the opinion of the investigator would preclude participation in the study other than physical symptoms or signs consistent with stable heart failure
    • An (ECG) with no abnormalities in the opinion of the investigator that would impair assessment of stopping criteria
  6. Patient has pre-study clinical laboratory findings that are within normal range, or if outside of the normal range, should not preclude participation in the study in the opinion of the investigator (see Exclusion Criteria, below, for exceptions)
  7. Patient has a documented diagnosis of heart failure with an of less than 40%
  8. Patient has been on a stable dose of a beta blocker and an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin II receptor blocker) for at least 4 weeks. If prescribed, diuretics must have been administered according to a consistent regimen for at least 4 weeks
  9. Patient is currently in sinus rhythm
  10. Patient has interpretable echocardiographic images on a screening echocardiogram

Exclusion criteria

Exclusion Criteria

  1. Patient has been hospitalized for heart failure, myocardial infarction, coronary revascularization, or another cardiac indication within the last 6 weeks
  2. Patient has a current history of alcohol use which in the opinion of the investigator would preclude participation in the study
  3. Patient has a current history of drug abuse
  4. Patient has donated blood or blood products within 30 days prior to screening
  5. Patient has Canadian Cardiovascular Society (CCS) Class III or IV angina
  6. Patient has significant obstructive valvular disease or significant congenital heart disease
  7. Patient has had a valve replacement
  8. Patient is pacemaker dependent
  9. Patient is on chronic anti-arrhythmic therapy, with the exception of amiodarone
  10. Patient is currently taking, or has taken in the last 7 days, a inhibitor or inducer medication
  11. Patient has a history of hypertrophic obstructive cardiomyopathy
  12. Patient weighs > 120 kg
  13. Patient has a supine resting systolic blood pressure \< 95 mmHg after 3 minutes rest
  14. Patient has a supine resting heart rate ≥ 100 beats per minute after 3 minutes rest
  15. Patient has an Modification of Diet in Renal Disease () estimate of Glomerular Filtration Rate (GFR) ≤ 35 ml/min/1.73 m2
  16. Patient has a potassium \< 3.5 mEq/L or > 5.5 mEq/L
  17. Patient has a sodium ≤ 133 mEq/L
  18. Patient has a urea > 15 mmole/L
  19. Patient has a troponin I or T at screening that is detectable at the investigative site's clinical laboratory
  20. Patient has a \< 11 gm/dL in males or \< 10 gm/dL in females
  21. Patient has an (ALT), aspartate transaminase (AST), alkaline phosphatase (ALKP) or total (TBILI) > 3 times the
  22. Patient is, in the opinion of the investigator, not suitable to participate in the study
  23. Patient has participated in any clinical study with an drug within three months prior to the first day of dosing with the exception of coronary stent studies Patient has ever received CK-1827452
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Cohort 1

    4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.

    Drug: CK-1827452 · Drug: Placebo

  • Experimental
    Cohort 2

    4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.

    Drug: CK-1827452 · Drug: Placebo

  • Experimental
    Cohort 3

    4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.

    Drug: Placebo · Drug: CK-1827452

  • Experimental
    Cohort 4

    4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.

    Drug: CK-1827452 · Drug: Placebo

  • Experimental
    Cohort 5

    2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1.

    Drug: CK-1827452 · Drug: Placebo

Interventions

  • IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h

  • IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h

  • IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h

  • IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h

  • IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h

  • IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h

  • IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h

  • IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h

  • DrugPlacebo

    IV infusion for 2 hours

  • DrugPlacebo

    IV infusion for 24 hours

  • IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h

  • DrugPlacebo

    IV infusion for 72 hours

  • IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h

  • IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h

  • IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h

  • IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h

06

What researchers measure

Primary outcomes

  1. Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations

    Pooled analysis of the echocardiographic measure systolic ejection time from echocardiograms taken at all timepoints. The systolic ejection time is the period during which the aortic valve is open and blood is flowing across the valve. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.

    Time frame: 4 days

  2. Change From Baseline of Fractional Shortening at Various CK-1827452 Plasma Concentrations

    Pooled analysis of the echocardiographic measure fractional shortening from echocardiograms taken at all timepoints. Fractional shortening is the percentage of change from baseline in the left ventricular cavity dimension with systole. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.

    Time frame: 4 days

Secondary outcomes

  1. CK-1827452 Maximum Observed Plasma Concentration (Cmax)

    Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion

    Time frame: 2 days

  2. CK-1827452 Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUClast)

    Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion

    Time frame: 2 days

07

Results

Posted Aug 16, 2010
Limitations and caveats
Other Adverse Event table shows treatment emergent adverse events that occurred in two or more patients. Total for Other Adverse Events is the number of patients affected by an adverse event where an adverse event occurred in two or more patients.

Participant flow

The recruitment period was from April 2007 to January 2009.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Started8910810
Completed88888
Not completed01202

Outcome measures

PrimaryChange From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations

Pooled analysis of the echocardiographic measure systolic ejection time from echocardiograms taken at all timepoints. The systolic ejection time is the period during which the aortic valve is open and blood is flowing across the valve. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.

Time frame:
4 days
Reported as:
Least squares mean · msec
Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations
msec>0-100 ng/mL>100-200 ng/mL>200-300 ng/mL>300-400 ng/mL>400-500 ng/mL>500 ng/mL
# of Echocardiographic Observations (no units)84 ± 062 ± 042 ± 024 ± 020 ± 046 ± 0
Ejection Fraction msec Change from Baseline1 ± 418 ± 447 ± 558 ± 659 ± 680 ± 5
Statistical analysis
  • >0-100 ng/mL · ANCOVA · p = 0.8842 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 1 · 95% CI -7 to 8ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >100-200 ng/mL · ANCOVA · p = <0.0001 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 18 · 95% CI 10 to 27ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >200-300 ng/mL · ANCOVA · p = <0.0001 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 47 · 95% CI 38 to 56ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >300-400 ng/mL · ANCOVA · p = <0.0001 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 58 · 95% CI 46 to 70ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >400-500 ng/mL · ANCOVA · p = <0.0001 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 59 · 95% CI 47 to 72ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >500 ng/mL · ANCOVA · p = <0.0001 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 80 · 95% CI 71 to 89ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >0-100 ng/mL vs >100-200 ng/mL vs >200-300 ng/mL vs >300-400 ng/mL vs >400-500 ng/mL vs >500 ng/mL · ANCOVA · p = <0.0001 (Threshold for statistical significance: p\<0.05)ANCOVA analysis based on the following model: Change from baseline = Concentration + Baseline + Error, treating patients as random effect
PrimaryChange From Baseline of Fractional Shortening at Various CK-1827452 Plasma Concentrations

Pooled analysis of the echocardiographic measure fractional shortening from echocardiograms taken at all timepoints. Fractional shortening is the percentage of change from baseline in the left ventricular cavity dimension with systole. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.

Time frame:
4 days
Reported as:
Least squares mean · Percentage of change
Change From Baseline of Fractional Shortening at Various CK-1827452 Plasma Concentrations
Percentage of change>0-100 ng/mL>100-200 ng/mL>200-300 ng/mL>300-400 ng/mL>400-500 ng/mL>500 ng/mL
# of Echocardiographic Observations (no units)81 ± 056 ± 037 ± 023 ± 017 ± 044 ± 0
Fractional Shortening Percent Change from Baseline1 ± 11 ± 13 ± 13 ± 12 ± 15 ± 1
Statistical analysis
  • >0-100 ng/mL · ANCOVA · p = 0.3665 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 1 · 95% CI -1 to 2ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >100-200 ng/mL · ANCOVA · p = <0.0357 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 1 · 95% CI 0 to 3ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >200-300 ng/mL · ANCOVA · p = 0.0004 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 3 · 95% CI 1 to 5ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >300-400 ng/mL · ANCOVA · p = 0.0086 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 3 · 95% CI 1 to 4ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >400-500 ng/mL · ANCOVA · p = 0.032 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 2 · 95% CI 0 to 5ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >500 ng/mL · ANCOVA · p = <0.0001 (p-value is not adjusted for multiple comparison Threshold for statistical significance: p\<0.05) · Lsm placebo corrected diff from baseline: 5 · 95% CI 3 to 6ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.
  • >0-100 ng/mL vs >100-200 ng/mL vs >200-300 ng/mL vs >300-400 ng/mL vs >400-500 ng/mL vs >500 ng/mL · ANCOVA · p = <0.0001 (Threshold for statistical significance: p\<0.05)ANCOVA analysis based on the following model: Change from baseline = Concentration + Baseline + Error, treating patients as random effect
SecondaryCK-1827452 Maximum Observed Plasma Concentration (Cmax)

Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion

Time frame:
2 days
Reported as:
Mean · nanogram/milliliter
CK-1827452 Maximum Observed Plasma Concentration (Cmax)
nanogram/milliliterCohort 1/2: 0.125 mg/kg/h + 0.0625 mg/kg/hCohort 1/2: 0.25 mg/kg/h + 0.125 mg/kg/hCohort 1/2: 0.5 mg/kg/h + 0.25 mg/kg/hCohort 1/2: 0.75 mg/kg/h + 0.375 mg/kg/hCohort 1/2: 1.0 mg/kg/h + 0.5 mg/kg/hCohort 3: 0.25 mg/kg/h + 0.025 mg/kg/hCohort 3: 0.5 mg/kg/h + 0.05 mg/kg/hCohort 3: 1.0 mg/kg/h + 0.1 mg/kg/hCohort 4: 0.25 mg.kg.h + 0.125 mg/kg/h + 0.025 mg/kg/hCohort 4: 0.5 mg/kg/h + 0.25 mg/kg/h + 0.05 mg/kg/hCohort 4: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/hCohort 5: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/hCohort 5: 0.75 mg/kg/h + 0.375 mg/kg/h + 0.075 mg/kg/h
CK-1827452 Maximum Observed Plasma Concentration (Cmax)96.1 ± 27.8195.0 ± 69.4347.1 ± 108.6558.1 ± 156.5635.9 ± 158.0165.3 ± 51.4279.9 ± 55.0633.0 ± 161.5177.9 ± 103.4403.3 ± 226.2681.4 ± 159.2884.5 ± 316.2726.9 ± 62.4
SecondaryCK-1827452 Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUClast)

Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion

Time frame:
2 days
Reported as:
Mean · hour x nanogram/milliliter
CK-1827452 Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUClast)
hour x nanogram/milliliterCohort 1/2: 0.125 mg/kg/h + 0.0625 mg/kg/hCohort 1/2: 0.25 mg/kg/h + 0.125 mg/kg/hCohort 1/2: 0.5 mg/kg/h + 0.25 mg/kg/hCohort 1/2: 0.75 mg/kg/h + 0.375 mg/kg/hCohort 1/2: 1.0 mg/kg/h + 0.5 mg/kg/hCohort 3: 0.25 mg/kg/h + 0.025 mg/kg/hCohort 3: 0.5 mg/kg/h + 0.05 mg/kg/hCohort 3: 1.0 mg/kg/h + 0.1 mg/kg/hCohort 4: 0.25 mg.kg.h + 0.125 mg/kg/h + 0.025 mg/kg/hCohort 4: 0.5 mg/kg/h + 0.25 mg/kg/h + 0.05 mg/kg/hCohort 4: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/hCohort 5: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/hCohort 5: 0.75 mg/kg/h + 0.375 mg/kg/h + 0.075 mg/kg/h
CK-1827452 Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUClast)1102.2 ± 257.62314.3 ± 640.94252.7 ± 1296.76060.7 ± 1741.78495.7 ± 3178.33982.7 ± 1070.28120.5 ± 2268.918450.7 ± 4747.84399.0 ± 1483.210624.8 ± 5168.319394.3 ± 4230.659044.6 ± 17693.243605.5 ± 3551.0

Adverse events

Collected over 5 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/41 (0%)8/41 (19.5%)
Cohorts 1 and/or 2, Loading Dose of 0.125 mg/kg/hr—0/8 (0%)1/8 (12.5%)
Cohorts 1 and/or 2, Loading Dose of 0.25 mg/kg/hr—0/9 (0%)0/9 (0%)
Cohorts 1 and/or 2, Loading Dose of 0.5 mg/kg/hr—0/16 (0%)1/16 (6.3%)
Cohorts 1 and/or 2, Loading Dose of 1.0 mg/kg/hr—0/6 (0%)4/6 (66.7%)
Cohorts 1 and/or 2, Loading Dose of 0.75 mg/kg/hr—0/8 (0%)0/8 (0%)
Cohort 2, Loading Dose of 2.2 mg/kg/hr—1/1 (100%)1/1 (100%)
Cohorts 3 and 4, Loading Dose of 0.25 mg/kg/hr—1/18 (5.6%)6/18 (33.3%)
Cohorts 3 and 4, Loading Dose of 0.5 mg/kg/hr—1/18 (5.6%)4/18 (22.2%)
Cohorts 3 and 4, Loading Dose of 1.0 mg/kg/hr—0/16 (0%)1/16 (6.3%)
Cohort 5, Loading Dose of 0.75 mg/kg/hr—0/2 (0%)1/2 (50%)
Cohort 5, Loading Dose of 1.0 mg/kg/hr—0/8 (0%)2/8 (25%)
Most frequent serious events
Most frequent serious events
EventPlaceboCohorts 1 and/or 2, Loading Dose of 0.125 mg/kg/hrCohorts 1 and/or 2, Loading Dose of 0.25 mg/kg/hrCohorts 1 and/or 2, Loading Dose of 0.5 mg/kg/hrCohorts 1 and/or 2, Loading Dose of 1.0 mg/kg/hrCohorts 1 and/or 2, Loading Dose of 0.75 mg/kg/hrCohort 2, Loading Dose of 2.2 mg/kg/hrCohorts 3 and 4, Loading Dose of 0.25 mg/kg/hrCohorts 3 and 4, Loading Dose of 0.5 mg/kg/hrCohorts 3 and 4, Loading Dose of 1.0 mg/kg/hrCohort 5, Loading Dose of 0.75 mg/kg/hrCohort 5, Loading Dose of 1.0 mg/kg/hr
Non ST elevation MI in patient with drug overdoseCardiac disorders0/410/80/90/160/60/81/10/180/180/160/20/8
Septicemia in setting of diabetic foot ulcerMetabolism and nutrition disorders0/410/80/90/160/60/80/11/180/180/160/20/8
PneumoniaInfections and infestations0/410/80/90/160/60/80/10/181/180/160/20/8
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboCohorts 1 and/or 2, Loading Dose of 0.125 mg/kg/hrCohorts 1 and/or 2, Loading Dose of 0.25 mg/kg/hrCohorts 1 and/or 2, Loading Dose of 0.5 mg/kg/hrCohorts 1 and/or 2, Loading Dose of 1.0 mg/kg/hrCohorts 1 and/or 2, Loading Dose of 0.75 mg/kg/hrCohort 2, Loading Dose of 2.2 mg/kg/hrCohorts 3 and 4, Loading Dose of 0.25 mg/kg/hrCohorts 3 and 4, Loading Dose of 0.5 mg/kg/hrCohorts 3 and 4, Loading Dose of 1.0 mg/kg/hrCohort 5, Loading Dose of 0.75 mg/kg/hrCohort 5, Loading Dose of 1.0 mg/kg/hr
Troponin increasedInvestigations0/410/80/90/160/60/81/10/180/180/160/22/8
Orthostatic hypotensionVascular disorders2/410/80/90/161/60/80/11/181/180/161/20/8
Dizziness posturalNervous system disorders0/410/80/90/161/60/80/11/181/180/160/20/8
HypotensionVascular disorders0/410/80/90/161/60/80/11/180/180/160/20/8
Sinus bradycardiaCardiac disorders0/410/80/90/161/60/80/10/180/180/160/21/8
Musculoskeletal painMusculoskeletal and connective tissue disorders1/411/80/90/160/60/80/10/180/180/160/20/8
SomnolenceNervous system disorders1/410/80/90/160/60/80/10/181/181/160/20/8
Urinary tract infectionInfections and infestations1/410/80/91/160/60/80/10/180/180/160/20/8
ConstipationGastrointestinal disorders2/410/80/90/160/60/80/11/180/180/160/20/8
DyspneaRespiratory, thoracic and mediastinal disorders1/410/80/90/160/60/80/11/180/180/160/20/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
<=18 years000000
Between 18 and 65 years5765730
>=65 years3243315
Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Mean59.0 ± 11.956.0 ± 14.362.0 ± 8.252.6 ± 18.057.0 ± 14.057.5 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Female010326
Male88105839
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
United States000123
Georgia000022
Russian Federation0442111
United Kingdom8565529
08

Study locations

17 sites
  • University of California, San Diego Medical Center
    San Diego, California 92103, United States
  • Christiana Care Health Services, Inc.
    Newark, Delaware 19713, United States
  • Diagnostic Services Clinic
    Tbilisi, Georgia
  • Russian Cardiological Research and Production Complex
    Moscow, 121552, Russian Federation
  • Dzhanelidze Research Institute for Emergency Medical Care
    St. Petersburg, 192242, Russian Federation
  • Almazov Federal Heart, Blood and Endocrinology Center
    St. Petersburg, 194156, Russian Federation
  • St. Petersburg State Medical University
    St. Petersburg, 197089, Russian Federation
  • Castle Hill Hospital, University of Hull
    Hull, England HU16 5JQ, United Kingdom
  • King's College Hospital
    London, England SE5 9RS, United Kingdom
  • St. George's Hospital
    London, England SW17 ORE, United Kingdom
  • St. Mary's Hospital & Imperial College
    London, England W2 1LA, United Kingdom
  • Manchester Heart Centre, Manchester Royal Infirmary
    Manchester, England M13 9WL, United Kingdom
  • ICON Development Solutions
    Manchester, England M15 6SH, United Kingdom
  • Wythenshawe Hospital
    Manchester, England M23 9LT, United Kingdom
  • Northwick Park Hospital
    Middlesex, England HA1 3UJ, United Kingdom
  • Ninewells Hospital and Medical School
    Dundee, Scotland DD1 9SY, United Kingdom
  • BHF Cardiovascular Centre
    Glasgow, Scotland G12 8TA, United Kingdom
09

References and documents

Publications

  • Vu T, Ma P, Xiao JJ, Wang YM, Malik FI, Chow AT. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. J Clin Pharmacol. 2015 Nov;55(11):1236-47. doi: 10.1002/jcph.538. Epub 2015 Jul 14. PubMed 25951506 ↗
  • Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011 Aug 20;378(9792):676-83. doi: 10.1016/S0140-6736(11)61126-4. PubMed 21856481 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2007
First posted
Feb 27, 2008
Start
Apr 2007
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Aug 16, 2010
Last update
May 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00624442
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Feb 27, 2008
Start date
Apr 2007
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Aug 16, 2010
Last update
May 14, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omecamtiv mecarbil

Start the discussion